These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27627692)

  • 21. Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia.
    Aghokeng AF; Monleau M; Eymard-Duvernay S; Dagnra A; Kania D; Ngo-Giang-Huong N; Toni TD; Touré-Kane C; Truong LX; Delaporte E; Chaix ML; Peeters M; Ayouba A;
    Clin Infect Dis; 2014 Jan; 58(1):99-109. PubMed ID: 24076968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
    Tebas P; Sension M; Arribas J; Duiculescu D; Florence E; Hung CC; Wilkin T; Vanveggel S; Stevens M; Deckx H;
    Clin Infect Dis; 2014 Aug; 59(3):425-34. PubMed ID: 24729492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrase inhibitors versus efavirenz combination antiretroviral therapies for TB/HIV coinfection: a meta-analysis of randomized controlled trials.
    Shu Y; Deng Z; Wang H; Chen Y; Yuan L; Deng Y; Tu X; Zhao X; Shi Z; Huang M; Qiu C
    AIDS Res Ther; 2021 May; 18(1):25. PubMed ID: 33933131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Birth defects following exposure to efavirenz-based antiretroviral therapy during pregnancy: a study at a regional South African hospital.
    Bera E; McCausland K; Nonkwelo R; Mgudlwa B; Chacko S; Majeke B
    AIDS; 2010 Jan; 24(2):283-9. PubMed ID: 19864931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients.
    Pereira SA; Batuca JR; Caixas U; Branco T; Delgado-Alves J; Germano I; Lampreia F; Monteiro EC
    Br J Clin Pharmacol; 2009 Dec; 68(6):891-7. PubMed ID: 20002083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa.
    Shearer K; Brennan AT; Maskew M; Long L; Berhanu R; Sanne I; Fox MP
    J Int AIDS Soc; 2014; 17(1):19065. PubMed ID: 25361827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.
    Gatanaga H; Hayashida T; Tsuchiya K; Yoshino M; Kuwahara T; Tsukada H; Fujimoto K; Sato I; Ueda M; Horiba M; Hamaguchi M; Yamamoto M; Takata N; Kimura A; Koike T; Gejyo F; Matsushita S; Shirasaka T; Kimura S; Oka S
    Clin Infect Dis; 2007 Nov; 45(9):1230-7. PubMed ID: 17918089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis.
    Cummins NW; Neuhaus J; Chu H; Neaton J; Wyen C; Rockstroh JK; Skiest DJ; Boyd MA; Khoo S; Rotger M; Telenti A; Weinshilboum R; Badley AD;
    EBioMedicine; 2015 Jul; 2(7):706-12. PubMed ID: 26288843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
    Maganda BA; Minzi OM; Ngaimisi E; Kamuhabwa AA; Aklillu E
    Pharmacogenomics J; 2016 Feb; 16(1):88-95. PubMed ID: 25963334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low body mass index and efavirenz use are independently associated with self-reported fatigue in HIV-infected patients.
    Wang K; Lin H; Li L; Wu Q; Shen W; Liu X; Gao M; Zhou S; Ding Y; He N
    AIDS Care; 2019 Apr; 31(4):513-518. PubMed ID: 30246544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuropsychiatric adverse drug reactions and associated factors in a cohort of individuals starting dolutegravir-based or efavirenz-based antiretroviral therapy in Belo Horizonte, Brazil.
    Mendes JC; Braga MDG; Reis AMM; Silveira MR
    Curr Med Res Opin; 2023 Apr; 39(4):523-531. PubMed ID: 36912019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women.
    Röhrich CR; Drögemöller BI; Ikediobi O; van der Merwe L; Grobbelaar N; Wright GE; McGregor N; Warnich L
    AIDS Res Hum Retroviruses; 2016 Jun; 32(6):529-38. PubMed ID: 26655325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful efavirenz dose reduction guided by therapeutic drug monitoring.
    Fayet Mello A; Buclin T; Decosterd LA; Delhumeau C; di Iulio J; Fleurent A; Schneider MP; Cavassini M; Telenti A; Hirschel B; Calmy A
    Antivir Ther; 2011; 16(2):189-97. PubMed ID: 21447868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
    Manosuthi W; Mankatitham W; Lueangniyomkul A; Chimsuntorn S; Sungkanuparph S
    HIV Med; 2008 May; 9(5):294-9. PubMed ID: 18400076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efavirenz conceptions and regimen management in a prospective cohort of women on antiretroviral therapy.
    Schwartz S; Taha TE; Venter WD; Mehta S; Rees H; Black V
    Infect Dis Obstet Gynecol; 2012; 2012():723096. PubMed ID: 22778534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.
    Ma Q; Vaida F; Wong J; Sanders CA; Kao YT; Croteau D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; Morgello S; Simpson DM; Heaton RK; Grant I; Letendre SL;
    J Neurovirol; 2016 Apr; 22(2):170-8. PubMed ID: 26407716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
    Fischl MA; Collier AC; Mukherjee AL; Feinberg JE; Demeter LM; Tebas P; Giuliano M; Dehlinger M; Garren K; Brizz B; Bassett R
    AIDS; 2007 Jan; 21(3):325-33. PubMed ID: 17255739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized crossover study to compare efavirenz and etravirine treatment.
    Nguyen A; Calmy A; Delhumeau C; Mercier IK; Cavassini M; Fayet-Mello A; Elzi L; Genné D; Rauch A; Bernasconi E; Hirschel B;
    AIDS; 2011 Jan; 25(1):57-63. PubMed ID: 21076278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study.
    Fernández-Bargiela N; Rotea-Salvo S; Margusino-Framiñán L; Balboa-Barreiro V; Martín-Herranz I; Castro-Iglesias Á; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Míguez-Rey E; Cid-Silva P
    Eur J Hosp Pharm; 2022 Jul; 29(4):207-211. PubMed ID: 33051194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.